Monopar Therapeutics Inc. (MNPR)
NASDAQ: MNPR · Real-Time Price · USD
40.25
-0.72 (-1.76%)
Feb 21, 2025, 4:00 PM EST - Market closed
Monopar Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Monopar Therapeutics stock have an average target of 43, with a low estimate of 10 and a high estimate of 72. The average target predicts an increase of 6.83% from the current stock price of 40.25.
Analyst Consensus: Strong Buy
* Price targets were last updated on Jan 22, 2025.
Analyst Ratings
The average analyst rating for Monopar Therapeutics stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 3 | 3 | 3 | 3 | 3 |
| Buy | 0 | 0 | 0 | 0 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 3 | 3 | 3 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $22 → $40 | Strong Buy | Maintains | $22 → $40 | -0.62% | Jan 22, 2025 |
| Piper Sandler | Piper Sandler | Buy Initiates $72 | Buy | Initiates | $72 | +78.88% | Jan 10, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $6 → $22 | Strong Buy | Maintains | $6 → $22 | -45.34% | Nov 11, 2024 |
| Rodman & Renshaw | Rodman & Renshaw | Strong Buy Initiates $50 | Strong Buy | Initiates | $50 | +24.22% | Oct 11, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $2 → $6 | Strong Buy | Maintains | $2 → $6 | -85.09% | Aug 14, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.81
from -3.04
EPS Next Year
-2.91
from -1.81
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | 29.6M | |||
| Avg | n/a | n/a | 14.8M | |||
| Low | n/a | n/a | 7.0M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -1.70 | -1.55 | 0.74 | |||
| Avg | -1.81 | -2.91 | -0.24 | |||
| Low | -1.98 | -3.99 | -1.16 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.